Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20323

Enrollment

350

Registered

2020-11-30

Start date

2021-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: 18 jaar or older; hospitalised for (suspicion of) COVID-19; written informed consent for those subjects admitted to the non-ICU clinical COVID-19 ward.

Exclusion criteria

Exclusion criteria: Subjects undergoing experimental interventions will be excluded.

Design outcomes

Primary

Measure	Time frame
Difference in sensitivity of blood plasma SAA, CRP , ferritin and PCT levels on day 1, day 3, day 5 and day 7 of hospital stay in patients with severe versus non-severe COVID-19 disease course.	—

Secondary

Measure	Time frame
• Specificity, positive and negative predictive values, positive and negative likelihood ratios SAA versus CRP, ferritin and PCT. • Clinical course of COVID-19 including classification of COVID-19 severity according to the WHO criteria (Clinical management of COVID-19 (who.int)). • Disease outcome at time of hospital discharge (or death).	—

Contacts

Public ContactNadine Pouw

Franciscus Gasthuis & Vlietland

n.pouw@franciscus.nl0031 10 4616091

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)